Peptide Imports to the U.S.: COAs and Paperwork to Reduce Detention Risk

Yes, researchers can import peptides into the United States, but every shipment passes through two agencies that decide its fate: the FDA and U.S. Customs and Border Protection. Clearance depends on having a Certificate of Analysis, manufacturer or establishment registration, and a clear research-use intended-use statement ready at entry. Shipments lacking this documentation risk detention without physical examination and, in some cases, administrative destruction.

TL;DR:

Labs should match the lot specific Certificate of Analysis, manufacturer registration, intended use statement, invoice, packing list, consignee name, HTS code, and compliance codes.

FDA import alerts allow detention without physical examination; release may require registered, listed manufacturers, compliant labeling, application linkage, or proof of legitimate research use.

FDA may destroy refused mail or express shipments worth $2,500 or less without an export option; detention also brings storage costs and testing delays.

Animal derived peptides may require an APHIS permit before arrival; CDC permits apply when shipments could involve infectious agents or vectors capable of carrying them.

Vertex Labs

Source Research Peptides with Traceable Documentation

Vertex Labs supplies research-use-only peptides with independent third-party testing and batch-specific Certificates of Analysis for research professionals.

Visit Vertex Labs

Who enforces import rules at U.S. ports: FDA and CBP’s division of labor
Import alerts, DWPE, and administrative destruction: how enforcement actually works
Documentation that actually secures clearance at entry
When USDA/APHIS or CDC rules apply to peptide shipments
What happens when a shipment gets detained, and how to respond
A practical checklist for preparing peptide imports
Regulatory evidence shaping current enforcement practice
Our perspective on responsible peptide procurement
Procurement support built around documentation
FAQ
Sources

Who enforces import rules at U.S. ports: FDA and CBP’s division of labor

The FDA and CBP perform distinct jobs at the border, and understanding the split matters more than most procurement teams realize. The FDA decides whether an imported article complies with federal law, including whether a peptide qualifies as an unapproved drug, a biologic, or a legitimately declared research material. CBP, by contrast, acts as the physical inspector and referral agent: it examines cargo, flags shipments that match FDA-regulated product codes, and holds them for FDA review when something looks off.

International mail and express couriers add another layer. Packages entering through these channels get screened against CBP’s entry data and, when peptide-related codes or descriptions appear, referred into FDA’s review queue automatically. This is where accurate paperwork earns its keep. A shipment that declares the correct manufacturer, carries the right Harmonized Tariff Schedule (HTS) code, and includes a proper Affirmation of Compliance (A of C) code moves through review far faster than one with vague or mismatched entry data. Sloppy or incomplete declarations are the single most common reason a routine research shipment turns into an extended detention. For labs and procurement officers, this means the paperwork prepared before a package ships often matters more than anything that happens after it lands.

Import alerts, DWPE, and administrative destruction: how enforcement actually works

Much of the enforcement risk around peptide imports traces back to a specific legal tool: the Import Alert. These alerts direct FDA field staff and CBP to detain shipments matching certain criteria without first physically examining them, a mechanism known as Detention Without Physical Examination, or DWPE. Import Alert 66-66 covers bulk drug substances and spells out what can secure release: registered and listed manufacturing firms, labeling that complies with federal drug labeling rules, a documented link to an approved or pending application, or clear evidence the material is intended for legitimate non-human research use.

Once a shipment lands on DWPE, the consequences escalate quickly. Since 2016, the FDA has held administrative destruction authority under the FDA Safety and Innovation Act, later expanded by the Safeguarding Therapeutics Act, allowing the agency to destroy refused drugs and devices valued at $2,500 or less arriving by mail or express courier without offering the importer a chance to export the goods instead. For a low-value peptide shipment, that means a documentation gap can result in the material being destroyed outright rather than returned.

Recent enforcement activity shows where agencies are focusing. In 2025, Cincinnati CBP uncovered a scheme that concealed thousands of peptide shipments inside master cartons, including GLP-1 active ingredients mixed in with other unapproved peptides. The case illustrates a consistent pattern: mis-manifestation and concealment, not peptides as a category, trigger the largest seizures and the most aggressive agency response.

Documentation that actually secures clearance at entry

An application number alone rarely satisfies FDA reviewers. Import Alert 66-66 notes that many importers fail specifically because they submit only a reference to an application without the supporting evidence FDA needs: a registered and listed foreign manufacturing firm, product listing records that match what’s declared, and a consignee name that lines up across every document in the shipment.

Affirmation of Compliance codes and HTS classifications do the practical work of telling FDA what kind of entry it’s looking at before a human reviewer ever opens the file. CBP’s Automated Commercial Environment guidance explains how product qualifiers and record identifiers signal FDA-regulated status and the affirmations required to clear it. Getting these codes wrong, or mismatched against the actual product, is one of the most common causes of unnecessary scrutiny.

For labs preparing a shipment, the practical document set looks like this:

A lot-specific Certificate of Analysis matching the exact batch being imported.
Manufacturer or establishment registration details for the supplying firm.
A written intended-use statement specifying non-human, laboratory research application.
An itemized invoice describing the material accurately, never as a cosmetic, supplement, or finished drug.
A detailed packing list with quantities that align with a credible research-scale justification.

Entries properly classified as basic scientific research or clinical-laboratory testing materials can avoid the heavier FDA drug-review pathway entirely, but only when the classification is accurate and the HTS code supports it. Misclassification, even when unintentional, is what pulls a shipment into deeper review.

When USDA/APHIS or CDC rules apply to peptide shipments

Not every regulatory question at the border belongs to FDA. When a peptide is animal-derived, or when a shipment includes materials that could carry livestock or poultry pathogens, USDA’s Animal and Plant Health Inspection Service may require a VS Form 16-6 or 16-3 import permit before the material ever reaches a U.S. port. APHIS guidance lists which animal-derived products need special attention and which are exempt, and checking this list before shipping avoids a delay that has nothing to do with FDA requirements at all.

CDC permits enter the picture only when a shipment could involve infectious agents or vectors capable of carrying them, a scenario distinct from most synthetic research peptide orders. Confirming exemption status early using APHIS’s published guidance can help determine whether a permit review may apply.

What happens when a shipment gets detained, and how to respond

Detention follows a fairly predictable pattern. CBP holds the shipment, flags it for FDA review, and FDA examines whatever documentation accompanies the entry: Certificate of Analysis, manufacturer registration and listing records, intended-use statements, and, where applicable, IND or BLA details tied to the claimed use. The agency is looking for consistency across every document, not just the presence of paperwork.

Outcomes vary depending on what’s submitted and how quickly. A consignee may be able to provide missing documentation and secure release, request reconditioning if the issue is a labeling defect rather than a substantive compliance gap, or, in cases involving refused low-value mail and express shipments, face administrative destruction without an export option. Storage costs accrue during detention, and testing delays can extend the timeline well beyond what a lab originally budgeted for a shipment.

When a shipment lands on an Import Alert, requesting removal from DWPE status requires submitting the specific evidence named in that alert, for instance, Import Alert 66-66 names registered firm status, listing records, compliant labeling, and application linkage as the categories of proof that support release. Contacting the FDA district office handling the detention with organized, clearly labeled evidence may help address the matter. Waiting for the agency to ask is slower than arriving prepared.

A practical checklist for preparing peptide imports

Most detentions are preventable with groundwork done before a package ever ships. The order matters less than making sure nothing is missing:

Pull the lot-specific Certificate of Analysis for the exact batch being shipped, not a generic product-level COA.
Confirm the manufacturer’s establishment registration and product listing are current and match what’s declared.
Write an intended-use statement specifying laboratory research application, in plain English, attached to the shipment.
Draft invoice language that describes the material accurately rather than using a generic or misleading category.
Prepare a packing list with quantities that make sense for a research order rather than a commercial resupply.

Labeling and manifesting deserve particular attention. A shipment manifested as a cosmetic, dietary supplement, or finished pharmaceutical when it’s actually a research peptide invites exactly the kind of scrutiny CBP has repeatedly flagged in seizure actions. Keep the research-use-only statement in English, visible, and consistent with the invoice description.

Before a shipment leaves the originating country, coordinate with the customs broker or carrier handling the entry to confirm the ACE entry fields, HTS code, and A of C qualifiers match the documentation package exactly. Our guide on how COAs and CAS records shape HS code selection walks through this matching process in more detail, and our overview of implementing research-use-only policies covers how to draft intended-use language that holds up under review.

Pro Tip: Keep the consignee name identical across the invoice, the COA, and the customs entry. A name mismatch is a common, easily avoided trigger for extended FDA review.

Regulatory evidence shaping current enforcement practice

Recent enforcement activity confirms a consistent focus. In 2025, Cincinnati CBP seized over $407,000 in unapproved pharmaceutical products, many mis-manifested as cosmetics or supplements rather than declared accurately. The GLP-1 receptor agonist Import Alert, updated for 2026, subjects those bulk drug substances to immediate DWPE absent proof of compliance or exemption. Across these cases, the pattern is the same: agencies prioritize mislabeling, unclear intended use, and unregistered manufacturing firms over the chemical identity of the peptide itself.

Our perspective on responsible peptide procurement

We believe traceability is the foundation of lawful research procurement, not an afterthought. Choosing suppliers who provide lot-level Certificates of Analysis and clear manufacturer documentation gives researchers the evidence customs and FDA reviewers actually look for. Every peptide we supply is intended strictly for laboratory research. For Research Use Only. Not for human or veterinary use.

— Vertex Labs Editorial Team

Procurement support built around documentation

We supply high-purity research peptides with batch-specific Certificates of Analysis to support lab quality control. Every compound in our catalog ships with batch-specific documentation.

Review current lot documentation on our Certificates of Analysis page before placing an order.
Browse High-Purity Research Peptides, Custom Peptide Sequences, and Bulk Procurement options for institutional and laboratory needs.
Explore Peptide Blends, Research Compounds, Sterile Solutions, and related product lines for additional research materials.

Reach out to our team about bulk procurement.

This article is general information, not a substitute for advice from a qualified lawyer. Consult a qualified legal professional about your own circumstances before acting on anything here.

FAQ

Can you import medicine into the US?

Importing medicine into the United States may involve FDA requirements that depend on the product and circumstances. Consult the FDA’s import basics guidance for the applicable framework. The FDA’s import basics guidance outlines the general framework, and unapproved drug products are routinely detained or destroyed at entry.

Is BPC-157 banned by NCAA?

Our catalog and sourcing focus on laboratory research supply, not athletic eligibility rules, so questions about NCAA banned-substance lists fall outside what we can address here. Researchers with that question should consult the NCAA’s official banned-substance resources directly.

What are some FDA-approved peptides?

A small number of peptides have gained FDA approval as drug products through the standard NDA or BLA pathway, but the vast majority of research peptides sold for laboratory use have not gone through that process and are not approved for any human or veterinary application. Research-use-only status is distinct from drug approval, and the two should never be conflated.

Can you sell peptides without being a doctor?

Whether a seller needs a particular license depends on the product, its intended use, and applicable requirements. Do not treat research-use-only labeling as a blanket legal exemption; consult authoritative guidance or qualified counsel. What matters legally is that labeling, intended-use statements, and marketing consistently reflect research-only use rather than clinical or therapeutic application.